Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma

Active, not recruiting

• Conditions: Melanoma; Renal Cell Carcinoma
• Interventions: Other: Blood collection for laboratory studies; Other: Data collection from medical record

• Registration Number: NCT03728842
• Lead Sponsor: Indiana University

Brief Summary

The purpose of this study is to collect blood and clinical data from patients with metastatic melanoma and renal cell cancer who have experienced spontaneous regression for studies of immune response and other factors that may influence these occurrences.

Detailed Description

Spontaneous regression in patients with metastatic cancer is an incredibly rare event. It has been described after infection in cancer patients and also rarely in patients with renal cell cancer (usually after resection of the renal primary) and, less commonly, in patients with metastatic melanoma.

Primary Objective To collect peripheral blood from patients with metastatic melanoma and renal cell cancer and spontaneous regression for studies of immune response and other studies.

Secondary Objective To collect clinical data from subjects registered to this study. Clinical data collection will include demographics and cancer characteristics, history and treatment.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2004-01-04
• Study First Submitted: 2018-10-05
• Study First Submitted QC: 2018-10-31
• Study First Posted: 2018-11-02
• Status Verified: 2024-07
• Last Update Submitted: 2024-07-15
• Last Update Posted: 2024-07-17
• Primary Completion: 2027-03-01
• Study Completion: 2027-03-01

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 19

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Spontaneous regression	Data collection from medical record	Patients must have metastatic melanoma or renal cell cancer with spontaneous regression.
Spontaneous regression	Blood collection for laboratory studies	Patients must have metastatic melanoma or renal cell cancer with spontaneous regression.

Primary Outcome Measures

Name	Time	Method
Number of blood samples collected	1 year	samples collected from metastatic melanoma and renal cell cancer patients

Trial Locations

Locations (1)

Indiana University Simon Cancer Center; 🇺🇸 Indianapolis, Indiana, United States